scispace - formally typeset
Journal ArticleDOI

The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex®) derivaties

TLDR
Chlorosubstituted derivatives of tacrine, 1,4-methylenetacrine, and their in vitro acetylcholinesterase and butyrylcholiersterase inhibitory activities are described.
About
This article is published in Bioorganic & Medicinal Chemistry Letters.The article was published on 1992-08-01. It has received 46 citations till now. The article focuses on the topics: Tacrine & Butyrylcholinesterase.

read more

Citations
More filters
Journal ArticleDOI

Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor.

TL;DR: Donepezil showed several positive characteristics including the following: It has a novel structure compared to other conventional ChE inhibitors; it shows strong anti-AChE activity and has long lasting efficacy; the inhibitory characteristic of donepezil shows that it is highly selective for AChE as compared to butyrylcholinesterase (BuChE) and showed reversibility.
Journal ArticleDOI

Targeting acetylcholinesterase to treat neurodegeneration.

TL;DR: The development of bivalent ligands that occupy both the active and the peripheral site of AChE might be more beneficial for treatment of Alzheimer´s disease than simple inhibition of the acetylcholine hydrolysis.
Journal ArticleDOI

Pyrano[3,2-c]quinoline−6-Chlorotacrine Hybrids as a Novel Family of Acetylcholinesterase- and β-Amyloid-Directed Anti-Alzheimer Compounds

TL;DR: Two isomeric series of dual binding site acetylcholinesterase (AChE) inhibitors that retain the potent and selective human AChE inhibitory activity of the parent 6-chlorotacrine while exhibiting a significant in vitro inhibitoryActivity toward the AChe-induced and self-induced Abeta aggregation and toward BACE-1, as well as ability to enter the central nervous system, which makes them promising anti-Alzheimer lead compounds.
Journal ArticleDOI

SAR of 9-Amino-1,2,3,4-tetrahydroacridine-Based Acetylcholinesterase Inhibitors: Synthesis, Enzyme Inhibitory Activity, QSAR, and Structure-Based CoMFA of Tacrine Analogues

TL;DR: This study attempted to derive a comprehensive SAR picture for the class of acetylcholinesterase (AChE) inhibitors related to tacrine, a drug currently in use for the treatment of the Alzheimer's disease.
References
More filters
Journal ArticleDOI

Enzyme inhibiting action of tetrahydroaminoacridine and its structural fragments

TL;DR: Tetrahydro‐5‐aminoacridine and four compounds representing its structural fragments have been compared as inhibitors of acetylcholinesterase and of monoamine oxidase, and 4‐Arninoquinoline shows a stronger monoamines oxidase inhibition than any known therapeutically used inhibitor.
Journal ArticleDOI

Role of butyrylcholinesterase in canine tracheal smooth muscle function

TL;DR: BuChE serves to coregulate the lifetime of ACh in canine tracheal smooth muscle by inhibiting ChE activity with little or no effect on AChE activity.
Journal Article

Interaction of tetrahydroaminoacridine with acetylcholinesterase and butyrylcholinesterase.

TL;DR: In this paper, tetrahydroaminoacridine (THA) was shown to associate with AchE and BuchE with high affinity and that subsequent inhibition comes about through ligand association at the active center rather than at a peripheral site.
Journal ArticleDOI

Differentiation and distribution of acetylcholinesterase molecular forms in the mouse cochlea.

TL;DR: The results indicate that in the cochlea the content of molecular forms is similar to that of other neuronal systems, the expression of AChE Molecular forms is developmentally regulated, and the ACh E isoenzymes develop and are distributed differentially along the coChlear length; resulting near maturity in the greater proportional expression of G4 and A12 in the base and midturn and G2/G1 in the apex.
Journal ArticleDOI

Tetrahydroaminoacridine in Alzheimer's dementia: Clinical and biochemical results of a double-blind crossover trial

TL;DR: The results indicate that THA has a therapeutic potential, although its pharmacokinetic profile and its liability to induce liver damage may limit the clinical use of the drug in the future.
Related Papers (5)